PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph plus ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.

被引：0
作者：
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
Paquette, Ronald
le Coutre, Philipp D.
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, Hanna Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Rea, Delphine
Abruzzese, Elisabetta
Mueller, Martin C.
Baccarani, Michele
Gambacorti-Passerini, Carlo
Turner, Christopher D.
Haluska, Frank G.
Kantarjian, Hagop
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Catholic Univ Korea, Seoul, South Korea
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[4] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[5] Charite, D-13353 Berlin, Germany
[6] Singapore Gen Hosp, Singapore, Singapore
[7] Ctr Hosp Lyon Sud, Pierre Benite, France
[8] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England
[9] Emory Winship Canc Inst, Atlanta, GA USA
[10] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[11] Washington Univ, Sch Med, St Louis, MO USA
[12] Dana Farber Canc Inst, Boston, MA 02115 USA
[13] Hop St Louis, Serv Malad Sang, Paris, France
[14] Osped S Eugenio, Rome, Italy
[15] Heidelberg Univ, Med Fak Mannheim, Med Klin 3, Mannheim, Germany
[16] Univ Hosp Bologna, Bologna, Italy
[17] Univ Milano Bicocca, Azienda Osped San Gerardo, Unita Ric Clin Ematol, Monza, Italy
[18] ARIAD Pharmaceut, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6503
引用
收藏
页数：2
相关论文
共 50 条
[31]   Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC [J].
Deininger, Michael ;
Apperley, Jane ;
Arthur, Christopher Kevin ;
Chuah, Charles ;
Hochhaus, Andreas ;
de Lavallade, Hugues ;
Lipton, Jeffrey Howard ;
Lomaia, Elza ;
McCloskey, James K. ;
Maness, Lori J. ;
Mauro, Michael J. ;
Moiraghi, Beatriz ;
Pavlovsky, Carolina ;
Rosti, Gianantonio ;
Rousselot, Philippe ;
Sutton, Maria Undurraga ;
Ren, Xiaowei ;
Vorog, Alexander ;
Kantarjian, Hagop M. ;
Cortes, Jorge E. .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[32]   Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study [J].
Nicolini, Franck E. ;
Heiblig, Mael ;
Morisset, Stephane ;
Caillot, Denis ;
Coiteux, Valerie ;
Charbonnier, Aude ;
Huguet, Francoise ;
Dubruille, Viviane ;
Etienne, Gabriel ;
Lenain, Pascal ;
Guilhot, Francois ;
Legros, Laurence ;
Rousselot, Philippe ;
Ame, Shanti ;
DeFrance, Remy ;
Ruby, Jeremy ;
Mahon, Francois-Xavier ;
Rea, Delphine .
BLOOD, 2015, 126 (23)
[33]   Innovative phase I-II study of concomitant and consecutive treatment with Dasatinib and MK-0457 in refractory Ph plus CML and ALL patients [J].
Papayannidis, Cristina ;
Lacobucci, Ilaria ;
Soverini, Simona ;
Paolini, Stefania ;
Santucci, Sandra ;
Cilloni, Daniela ;
Messa, Francesca ;
Pane, Fabrizio ;
Meneghini, Vittorio ;
Giannoulia, Panagiota ;
Ottaviani, Emanuela ;
Testoni, Nicoletta ;
Lama, Barbara ;
Pantaleo, Maria ;
Baccarani, Michele ;
Martinelli, Giovanni .
CANCER RESEARCH, 2009, 69
[34]   Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial. [J].
Mueller, Martin ;
Baccarani, Michele ;
Deininger, Michael W. N. ;
Guilhot, Francois ;
Hochhaus, Andreas ;
Hughes, Timothy P. ;
Shah, Neil P. ;
Talpaz, Moshe ;
Lustgarten, Stephanie ;
Santillana, Sergio ;
Rivera, Victor M. ;
Clackson, Timothy Piers ;
Cortes, Jorge E. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[35]   Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation - Results of An Ongoing Multicenter Phase II Study [J].
Cortes, Jorge ;
Khoury, H. Jean ;
Corm, Selem ;
Nicolini, Franck E. ;
Lipton, Jeffrey H. ;
Jones, Dan ;
Hochhaus, Andreas ;
Craig, Adam R. ;
Benichou, Annie-Claude ;
Humphriss, Eric ;
Kantarjian, Hagop .
BLOOD, 2008, 112 (11) :1112-1113
[36]   Phase I study of nilotinib in patients (pts) from Japan with imatinib-resistant Ph plus chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) [J].
Tojyo, A. ;
Miyazaki, Y. ;
Usui, N. ;
Kobyashi, Y. ;
Okamoto, S. ;
Oyashiki, K. ;
Nishimura, M. ;
Okada, M. ;
Natori, H. ;
Tanii, H. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[37]   INNOVATIVE PHASE I STUDY OF CONCOMITANT AND CONSECUTIVE TREATMENT WITH DASATINIB AND MK-0457 IN REFRACTORY PH plus CML AND ALL PATIENTS [J].
Papayannidis, C. ;
Iacobucci, I. ;
Soverini, S. ;
Paolini, S. ;
Santucci, S. ;
De Rosa, F. ;
Cilloni, D. ;
Messa, F. ;
Pane, F. ;
Meneghini, V ;
Giannoulia, P. ;
Ottaviani, E. ;
Testoni, N. ;
Lama, B. ;
Baccarani, M. ;
Martinelli, G. .
HAEMATOLOGICA, 2008, 93 :S65-S65
[38]   Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory Ph plus CML and ALL patients [J].
Papayannidis, C. ;
Iacobucci, I. ;
Soverini, S. ;
Paolini, S. ;
Cilloni, D. ;
Messa, F. ;
Pane, F. ;
Ottaviani, E. ;
Baccarani, M. ;
Martinelli, G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[39]   A phase II study of nilotinib, a novel tyrosine vinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph plus acute lymphoblastic leukemia (ALL). [J].
Ottmann, Oliver ;
Kantarjian, Hagop ;
Larson, Richard ;
le Courte, Philipp ;
Baccarani, Michele ;
Rafferty, Teresa ;
Weitzman, Aaron ;
Giles, Francis .
BLOOD, 2006, 108 (11) :528A-528A
[40]   Dasatinib phase I/II study of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib: Results of the CA180031 study in Japan [J].
Sakamaki, H. ;
Ishizawa, K. ;
Taniwaki, M. ;
Fujisawa, S. ;
Morishima, Y. ;
Tobinai, K. ;
Okada, M. ;
Ando, K. ;
Ueda, K. ;
Ohno, R. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345